We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




XL Dermal Graft Matrix Supports Reconstructive Surgery

By HospiMedica International staff writers
Posted on 10 Nov 2021
Print article
Image: The new AlloMend extra-large ADM (Photo courtesy of AlloSource)
Image: The new AlloMend extra-large ADM (Photo courtesy of AlloSource)
A new acellular dermal matrix (ADM) with a large footprint aids demanding soft tissue applications in plastic and reconstructive surgery.

The AlloSource (Centennial, CO, USA) AlloMend Extra-Large (XL) ADM comes in meshed and non-meshed varieties, with a footprint of 16cm x 20cm (320 cm2) for use in demanding soft tissue applications, with both options featuring a one cm non-meshed border for secure and easy suturing. The increased surface area also enables increased fluid egress, helping protect the area from seroma formation. Additionally, the meshing allows graft expansion to provide greater adaptability in reconstruction procedures.

AlloMend ADM is processed using proprietary DermaTrue decellularization process, which removes cellular debris (including DNA, RNA, proteins, and antigens), rendering the tissue acellular and with low immunologic response, while still retaining growth factors and a collagen structure. In addition, terminal sterilization with e-beam technology to a sterility assurance level (SAL) of 10-6, minimizes infection risk, while avoiding damaging the allograft tissue. AlloMend ADM is also shelf-stable and comes pre-hydrated, so it is immediately ready-to-use.

“Based on AlloSource's twenty seven years of manufacturing skin grafts, we have seen surgeons switch to new reconstruction techniques, which requires larger dermal grafts for single piece coverage,” said Ross Wilkins, MD, senior medical director of AlloSource. “AlloMend XL was created with the purpose to help surgeons provide better options for outcomes for their patients.”

Enhancing fluid egress reduces the risk of seroma, which can slow vascular ingrowth and postpone integration of a tissue graft. Further, increasing the surface area of an ADM graft that comes in contact with the patient’s vascularized native tissue may allow for more rapid vascularization and faster patient recovery.

Related Links:
AlloSource

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Vein Illuminator
VSI

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.